Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

The reverse transcriptase inhibitor efavirenz is currently used at a fixed dose of 600 mg/d. However, dosage individualization based on plasma concentration monitoring might be indicated. This study aimed to assess the efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus, to explore the relationship between drug exposure, efficacy, and central nervous system toxicity and to build up a Bayesian approach for dosage adaptation.


Published in:
Clinical pharmacology and therapeutics, 73, 1, 20-30
Year:
2003
Publisher:
Elsevier
ISSN:
0009-9236
Laboratories:




 Record created 2011-04-15, last modified 2018-09-13


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)